NDA 201532 · Eisai INC
Halaven
Eribulin Mesylate · Intravenous
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Sep 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Nov 15, 2010
Approved uses
3
Original approval plus efficacy supplements
Registered trials
245
59 Phase 3, 40 recruiting
FAERS reports
3,739
3,465 serious, 663 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 26, 2026.
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 13, 2022 Supplement 23 · Efficacy · priority review LetterLabel
- Jan 28, 2016 Supplement 15 · Efficacy · priority review OrphanLetterLabel
- Nov 15, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- HALAVEN · ERIBULIN MESYLATE 1MG/2ML (0.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Eribulin" as an intervention, any sponsor and status, largest first.
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT02299999 · 1,460 participants · Start Apr 7, 2014 · Primary completion Dec 2022
Drug: AZD2014; AZD4547 and 17 more · For: Metastatic Breast Cancer
Sites: Angers, France; Avignon, France; Bordeaux, France · 25 sites in all
- E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00337103 · 1,276 participants · Start Sep 20, 2006 · Primary completion Mar 12, 2012
Drug: Eribulin Mesylate; Capecitabine · For: Metastatic Breast Cancer
Sites: Anaheim, California; La Verne, California; Poway, California · 169 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
- The BEACON Study (Breast Cancer Outcomes With NKTR-102)Pivotal-lookingCompleted
Nektar TherapeuticsIndustry
NCT01492101 · 852 participants · Start Dec 2011 · Primary completion Apr 2016
Drug: NKTR-102; Treatment of Physician's Choice (TPC) · For: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Sites: Flagstaff, Arizona; Burbank, California; Los Angeles, California · 153 sites in all
- E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast CancerPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00388726 · 762 participants · Start Nov 2006 · Primary completion May 2009
Drug: E7389; Physician's Choice · For: Breast Cancer
Sites: Birmingham, Alabama; Bellflower, California; Gilroy, California · 137 sites in all
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05104866 · 732 participants · Start Oct 18, 2021 · Primary completion Jul 24, 2024
Drug: Dato-DXd; Capecitabine and 3 more · For: Breast Cancer
Sites: Duarte, California; Los Angeles, California; Palo Alto, California · 167 sites in all
- A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05374512 · 644 participants · Start May 16, 2022 · Primary completion Aug 25, 2025
Drug: Dato-DXd; Paclitaxel and 4 more · For: Breast Cancer
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 228 sites in all
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerPivotal-lookingCompleted
MacroGenicsIndustry
NCT02492711 · 624 participants · Start Aug 24, 2015 · Primary completion Aug 11, 2021
Drug: Margetuximab; Trastuzumab and 1 more · For: HER-2 Positive Breast Cancer; Metastatic Neoplasm
Sites: Chandler, Arizona; Gilbert, Arizona; Goodyear, Arizona · 167 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia538
- malignant neoplasm progression383
- febrile neutropenia331
- myelosuppression318
- pyrexia216
- neuropathy peripheral214
- leukopenia208
- interstitial lung disease181
- white blood cell count decreased177
- neutrophil count decreased171
- fatigue159
- nausea157
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 74 |
| 2012 | 247 |
| 2013 | 213 |
| 2014 | 161 |
| 2015 | 334 |
| 2016 | 383 |
| 2017 | 354 |
| 2018 | 281 |
| 2019 | 255 |
| 2020 | 196 |
| 2021 | 243 |
| 2022 | 273 |
| 2023 | 337 |
| 2024 | 189 |
| 2025 | 120 |
| 2026 | 78 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Halaven (Eribulin Mesylate)
2024 spending
$281K
Beneficiaries
14
40 claims
Per beneficiary
$20,076
$682.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,193,528 |
| 2021 | $870,082 |
| 2022 | $865,201 |
| 2023 | $618,194 |
| 2024 | $281,060 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M, Im SA, Senkus E, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS, Bardia A, Marmé F, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Rugo HS, Bardia A, Marmé F, et al. · J Clin Oncol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J, O'Shaughnessy J, Loesch D, et al. · Lancet 2011 · Clinical Trial, Phase III, Comparative Study
Sponsor: Eisai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.